NCT03222674Not yet recruitingPhase 1/2
Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
Multi-center Phase I/II Clinical Trial of Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
Source: ClinicalTrials.gov · Last updated 2 Nov 2026
Brief summary (registry, in English)
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of multi-CAR T cell therapy targeting different AML surface antigens in patients with relapsed or refractory acute myeloid leukemia (AML). Another goal of the study is to learn more about the function of the multi-CAR T cells and their persistency in the patients.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- First submitted
- 14 Jul 2017
- Start date
- 31 Dec 2026
- Primary completion date
- 30 Jun 2028
- Lead sponsor
- Shenzhen Geno-Immune Medical Institute
- Diseases
- Acute myeloid leukemia, Childhood cancers
- NCT number
- NCT03222674
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 10
- From 31 Dec 2026 to the primary completion date, 30 Jun 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
This page is information, not medical advice. Discuss any trial with your doctor.